About Caribou Biosciences
Caribou Biosciences is a company based in Berkeley (United States) founded in 2011 by Jennifer Doudna, James Berger, and Martin Jinek.. Caribou Biosciences has raised $156.55 million across 6 funding rounds from investors including AbbVie, Pfizer and Novartis. The company has 147 employees as of December 31, 2024. Caribou Biosciences offers products and services including chRDNA Technology and CAR-T Cell Therapies. Caribou Biosciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Berkeley, United States
- Employees 147 as on 31 Dec, 2024
- Founders Jennifer Doudna, James Berger, Martin Jinek
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Caribou Biosciences, Inc.
-
Annual Revenue
$9.99 M-71.01as on Dec 31, 2024
-
Net Profit
$-149.1 M-46.08as on Dec 31, 2024
-
EBITDA
$-162.69 M-44.57as on Dec 31, 2024
-
Total Equity Funding
$156.55 M (USD)
in 6 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jun 29, 2023
-
Investors
AbbVie
& 24 more
-
Employee Count
147
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Caribou Biosciences
Caribou Biosciences is a publicly listed company on the NASDAQ with ticker symbol CRBU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Caribou Biosciences
Caribou Biosciences offers a comprehensive portfolio of products and services, including chRDNA Technology and CAR-T Cell Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables precise CRISPR-based editing for gene knockout and insertion.
Develops off-the-shelf treatments for hematologic malignancies and diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
25 people
Scientific Team
10 people
Software Development Team
6 people
Finance and Accounting
5 people
Operations Team
4 people
Legal and Compliance
4 people
Human Resources and Administration
2 people
Senior Team
2 people
Unlock access to complete
Funding Insights of Caribou Biosciences
Caribou Biosciences has successfully raised a total of $156.55M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $25.0M
-
First Round
First Round
(01 May 2013)
- Investors Count 25
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Post-IPO - Caribou Biosciences | Valuation |
investors |
|
| Mar, 2021 | Amount | Series C - Caribou Biosciences | Valuation | Farallon Capital Management , Ridgeback Capital Management | |
| May, 2016 | Amount | Series B - Caribou Biosciences | Valuation | Anterra Capital , Heritage Group |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Caribou Biosciences
Caribou Biosciences has secured backing from 25 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Pfizer and Novartis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple investment strategies are pursued by this hedge fund.
|
Founded Year | Domain | Location | |
|
Ridgeback Capital is focused on healthcare and life science investments.
|
Founded Year | Domain | Location | |
|
Early-stage tech and life-sciences firms are funded across the US.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Caribou Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Caribou Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Caribou Biosciences Comparisons
Competitors of Caribou Biosciences
Caribou Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Caribou Biosciences
Frequently Asked Questions about Caribou Biosciences
When was Caribou Biosciences founded?
Caribou Biosciences was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Where is Caribou Biosciences located?
Caribou Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Is Caribou Biosciences a funded company?
Caribou Biosciences is a funded company, having raised a total of $156.55M across 6 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on May 01, 2013.
How many employees does Caribou Biosciences have?
As of Dec 31, 2024, the latest employee count at Caribou Biosciences is 147.
What is the annual revenue of Caribou Biosciences?
Annual revenue of Caribou Biosciences is $9.99M as on Dec 31, 2024.
What does Caribou Biosciences do?
Caribou Biosciences was founded in 2011 in Berkeley, United States, within the biotechnology sector. Cellular engineering and analysis solutions are developed based on CRISPR-Cas9 biology. These tools are applied across therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia have been created, as have iPSC-derived CAR-NK therapies targeting solid tumors. Operations focus on advancing treatments for hematologic and oncologic conditions.
Who are the top competitors of Caribou Biosciences?
Caribou Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Caribou Biosciences offer?
Caribou Biosciences offers chRDNA Technology and CAR-T Cell Therapies.
Is Caribou Biosciences publicly traded?
Yes, Caribou Biosciences is publicly traded on NASDAQ under the ticker symbol CRBU.
Who are Caribou Biosciences's investors?
Caribou Biosciences has 25 investors. Key investors include AbbVie, Pfizer, Novartis, Janus Henderson Investors, and Farallon Capital Management.
What is Caribou Biosciences's ticker symbol?
The ticker symbol of Caribou Biosciences is CRBU on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.